Results 131 to 140 of about 58,001 (251)

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Fel d 1‐Expressing Plant‐Derived Bioparticle: A Novel Treatment for Cat Allergy

Allergy, EarlyView.
This study investigates the allergenicity and immunogenicity profile of a novel plant‐derived Fel d 1 bioparticle (eBP). Fel d 1 eBP promotes immune tolerance by redirecting allergic Th2 responses toward Th1 and IL‐10–producing regulatory pathways, including Bregs.
Janice A. Layhadi, Liliana Cifuentes Gutierrez, Sean T. Keane, William Fulton, Nichell A. Samson, Lily Y. D. Wu, Paulina Filipaviciute, Prista Hikmawati, Oleksandra Fedina, Ana Jimenez‐Gil, Stephen R. Durham, Guy Scadding, Guy Tropper, Louis‐Philippe Vézina, Patrick Colin, Ronald van Ree, Mohamed H. Shamji   +16 more
wiley   +1 more source

A Case for Anti‐IgE Vaccination

Allergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff, Zahra Gharailoo, Monique Vogel, Martin F. Bachmann   +3 more
wiley   +1 more source

The Testicular Cancer Consortium (TECAC): Filling Knowledge Gaps in the Genetic Etiology of Testicular Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Background The Testicular Cancer Consortium (TECAC) was established in 2012 and is comprised of researchers from over 25 centers in Europe and North America. TECAC's overarching goal is to investigate the genetic susceptibility of testicular germ cell tumors (TGCT) to better understand their biology, impact prevention strategies, and inform ...
Peter A. Kanetsky, Kristian Almstrup, Svetlana Cherlin, Victoria K. Cortessis, Alberto Ferlin, Jourik A. Gietema, Anna González‐Neira, Tom Grotmol, Robert J. Hamilton, Trine B. Haugen, Lambertus A. Kiemeney, Jung Kim, Csilla Krausz, Davor Lessel, Ragnhild A. Lothe, Kevin T. Nead, Jérémie Nsengimana, Jenny N. Poynter, Ewa Rajpert‐DeMeyts, Lorenzo Richiardi, Stephen M. Schwartz, Rolf I. Skotheim, Douglas R. Stewart, Clare Turnbull, Fredrik Wiklund, Tongzhang Zheng, Katherine L. Nathanson, Katherine A. McGlynn, for the Testicular Cancer Consortium   +28 more
wiley   +1 more source

Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer. [PDF]

J Clin Invest, 2023
Nishio K, Pasquet L, Camara K, DiSapio J, Hsu KS, Kato S, Bloom A, Richardson SK, Welsh JA, Jiang T, Jones JC, Cardell S, Watarai H, Terabe M, Olkhanud PB, Howell AR, Berzofsky JA.   +16 more
europepmc   +1 more source

Bayesian inference for dynamic Q matrices and attribute trajectories in hidden Markov diagnostic classification models

British Journal of Mathematical and Statistical Psychology, EarlyView.
Abstract Hidden Markov diagnostic classification models capture how students' cognitive attributes evolve over time. This paper introduces a Bayesian Markov chain Monte Carlo algorithm for diagnostic classification models that jointly estimates time‐varying Q matrices, latent attributes, item parameters, attribute class proportions and transition ...
Chen‐Wei Liu
wiley   +1 more source

CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. [PDF]

Cancer Cell Int, 2023
Hadiloo K, Tahmasebi S, Esmaeilzadeh A.
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

The role of natural killer T cells in liver transplantation

Frontiers in Cell and Developmental Biology
Natural killer T cells (NKTs) are innate-like lymphocytes that are abundant in the liver and participate in liver immunity. NKT cells express both NK cell and T cell markers, modulate innate and adaptive immune responses. Type I and Type II NKT cells are
Wenchao Zhao, Mingqian Li, Shifei Song, Yao Zhi, Chen Huan, Guoyue Lv   +5 more
doaj   +1 more source

Cytosolic delivery of bacterial metabolites by riboflavin transporters promotes MR1 antigen presentation and MAIT cell recognition

Immunology &Cell Biology, EarlyView.
VitBAg antigen presentation is promoted through a cytosolic pathway that reaches ligand‐receptive MR1 to present to MAIT cells, like the riboflavin transport pathway. Riboflavin solute carrier transporters can promote this MR1 presentation, but they are not essential for this role, suggesting redundant pathways to uptake VitBAg.
Sebastian Cruz‐Gomez, Hui Jing Lim, Brunda Nijagal, Yuting Yang, Nicole Lau, Jeffrey YW Mak, David P Fairlie, Hayley Newton, Mariolina Salio, Jose A Villadangos, Hamish EG McWilliam   +10 more
wiley   +1 more source